… in the glucocerebrosidase gene (GBA1) are the most common genetic risk factor for Parkinson disease. GBA1 mutations lead to a shortage … activity in the lysosome. These assays will be tested in neurons that we generate by engineering skin cells …

… Partners in Parkinson’s launches today, inviting Parkinson’s patients, caregivers and families to take hold of two of the greatest tools for managing Parkinson’s disease: knowledge and … a partnership of The Michael J. Fox Foundation and AbbVie, combines web-based and “in real life” opportunities to …

… Study Rationale:     As new targeted therapies for Parkinson’s disease (PD) enter clinical trials, it will be important to develop biomarkers that will allow clinicians to match … and genetic PD and will identify the most appropriate tests for future studies.   Study Design: We will use an …

… protein accumulation in the brain causes neurotoxicity in Parkinson’s disease (PD). Neural cells have a … not function as efficiently. The experimental therapeutic compound, OXD-5, has UPS-stimulating activity, so we will … to PD models. Postmortem analysis of brain tissue samples showed that administration of OXD-5 drug penetration within …

… Editor’s Note (June 15, 2021): Today, national science … approval of aducanumab for the treatment of Alzheimer’s and how it is “just the beginning of a pipeline of therapies … study design in Alzheimer’s. Parkinson’s is the second most common degenerative brain disease after Alzheimer’s. The two …

… of Parkinson’s disease (PD) is growing but remains far from complete. Unfortunately, most of this research has not been … Parkinson’s. As a result, we have an incomplete picture of how PD affects patients and families across racial, ethnic, … socioeconomic, gender, sexuality and geographic spectrums. To address the knowledge gap, The Michael J. Fox Foundation …